News

Bookmark and Share

Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease

Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease
Roger BarkerRoger Barker (Clinical Neurosciences and Wellcome–MRC Stem Cell Institute) explores the clinical studies of Parkinson’s disease (PD), using a dopamine cell replacement strategy, that have been in progress for more than 30 years. The mesencephalic tissue trials have been variable, with some patients coming off their anti-PD treatment for many years and others not responding and/or developing significant side effects which has led to a re-appraisal of the best way to do such trials.  
 
Published in Nature Medicine the rationale behind a new European Union funded allograft trial with foetal dopamine cells across several centres in Europe, the TRANSEURO (NCT01898390) trial, is discussed. While completion of TRANSEURO is not expected until 2021, sharing the rationale for the design, along with the lessons learnt, can help inform researchers and facilitate planning of transplants of dopamine-producing cells derived from human pluripotent stem cells for future clinical trials, which are planned to start in Cambridge in late 2020 early 2021.

Posted on 16/08/2019

Further news

Go to the news index page.